Covered recipient · General Payments record
MOHAMED ATTA
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$39,728.62
- Reported across 77 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,150.00 | 2 |
| Travel and Lodging | $1,767.65 | 7 |
| Food and Beverage | $663.29 | 11 |
| Education | $7.47 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $5,482.34 | 10 |
| CALLIDITAS THERAPEUTICS US INC. | $3,000.00 | 1 |
| GlaxoSmithKline, LLC. | $1,016.43 | 8 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $82.17 | 1 |
| Retrophin, Inc. | $7.47 | 3 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (23)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20182019202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $121.05 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115431313 | CMS |
| Amgen Inc. | $226.86 | 06/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115431316 | CMS |
| Amgen Inc. | $350.00 | 06/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115431320 | CMS |
| Amgen Inc. | $410.95 | 06/20/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115431324 | CMS |
| Amgen Inc. | $25.00 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115431328 | CMS |
| Amgen Inc. | $25.00 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115431334 | CMS |
| Amgen Inc. | $50.00 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115431338 | CMS |
| Amgen Inc. | $50.00 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115431341 | CMS |
| Amgen Inc. | $73.48 | 06/21/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115431346 | CMS |
| Amgen Inc. | $4,150.00 | 06/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1115431350 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $3,000.00 | 09/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141523357 | CMS |
| GlaxoSmithKline, LLC. | $31.02 | 11/15/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1116564220 | CMS |
| GlaxoSmithKline, LLC. | $402.88 | 11/15/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1116607758 | CMS |
| GlaxoSmithKline, LLC. | $272.46 | 12/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1116478399 | CMS |
| GlaxoSmithKline, LLC. | $123.23 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116716171 | CMS |
| GlaxoSmithKline, LLC. | $64.93 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116239639 | CMS |
| GlaxoSmithKline, LLC. | $55.65 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116345818 | CMS |
| GlaxoSmithKline, LLC. | $19.88 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116484799 | CMS |
| GlaxoSmithKline, LLC. | $46.38 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116711599 | CMS |
| Novartis Pharmaceuticals Corporation | $82.17 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086618451 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 01/11/2024 | Education | Undisputed | 01/23/2026 | 1149951473 | CMS |
| Travere Therapeutics, Inc. | $1.31 | 03/21/2024 | Education | Undisputed | 01/23/2026 | 1149951466 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 07/22/2024 | Education | Undisputed | 01/23/2026 | 1149951479 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.